Pepteligence
Share
Medical notice — For research and educational purposes only. Not medical advice. Consult a licensed physician before using any peptide or compound.

Best peptides for fat loss

Fat loss peptides range from FDA-approved GLP-1 receptor agonists — some of the most extensively studied weight-loss medications ever developed — to experimental metabolic compounds with only animal-model data. This list is organized by strength of evidence, not hype. Every entry is derived from the research we've indexed; no compound is positioned as universally "best."

  1. 1

    Semaglutide

    FDA-approvedTier 1 — FDA-approved

    Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist with the strongest evidence base for fat loss of any peptide on this list — multiple Phase 3 RCTs with thousands of participants, FDA approval for obesity (Wegovy), and real-world data confirming 10–15% average body weight loss at the 2.4 mg weekly dose. Its mechanism reduces appetite via central GLP-1 receptors and slows gastric emptying.

    Full Semaglutide profile →
  2. 2

    Tirzepatide

    FDA-approvedTier 1 — FDA-approved

    Tirzepatide (Mounjaro, Zepbound) adds GIP receptor agonism to GLP-1 signaling, producing greater average weight loss than semaglutide in head-to-head data (SURMOUNT-5: ~20% vs ~14% at 72 weeks). FDA-approved for type 2 diabetes and obesity with a large Phase 3 trial program. Currently the highest-efficacy approved obesity pharmacotherapy in the literature.

    Full Tirzepatide profile →
  3. 3

    Tesamorelin

    FDA-approvedTier 2 — Phase 3 RCT data

    Tesamorelin (Egrifta) is an FDA-approved GHRH analog with Phase 3 RCT evidence specifically for reducing excess visceral adipose tissue in HIV-positive patients with lipodystrophy. Its GH-stimulating mechanism targets visceral fat rather than systemic obesity. Use outside this specific indication is off-label with a thinner evidence base.

    Full Tesamorelin profile →
  4. 4

    MOTS-c

    Tier 3–4 — Preclinical

    MOTS-c is a mitochondrial-derived peptide that activates AMPK, a cellular energy sensor that promotes fat oxidation and insulin sensitivity in animal studies. Proposed to improve metabolic function and body composition in aging models. All current evidence is preclinical; no human clinical trials for fat loss have been published.

    Full MOTS-c profile →

Evidence tiers on this page reflect how we classify research quality — Tier 1 (FDA-approved with Phase 3 RCTs) through Tier 4 (anecdotal only). Read how we evaluate evidence at our methodology page.

How we evaluate evidence →
← All goal categoriesBrowse all peptides →